PL EN


Preferences help
enabled [disable] Abstract
Number of results
2013 | 11 | 2 | 103–114
Article title

Ocena oznaczeń markera TATI – trzustkowego inhibitora trypsyny – u chorych na raka trzonu macicy z niekorzystnymi czynnikami rokowniczymi

Content
Title variants
EN
Evaluation of TATI marker assays – the pancreatic trypsin inhibitor – in patients with endometrial cancer with unfavorable predictors
Languages of publication
EN
Abstracts
EN
TATI marker (tumor-associated trypsin inhibitor) is most often assessed in patients with ovarian cancer. This paper presents the role and the usefulness of the marker in the evaluation of the treatment results in patients with endo­metrial cancer. The study was based on the evaluation of TATI marker level in 305 patients suffering from endo­metrial cancer treated at the Cancer Center between 1994 and1995 in Warsaw. In each patient the TATI marker level was measured from 3 to 7 times in the blood serum after each stage of the adjuvant treatment and in the ini­tial part of the follow-up period. In order to assess the staging a postoperative protocol in force in 1988 (FIGO) was used and in accordance with this protocol, the patients were qualified for the adjuvant therapy, which consisted of the teletherapy, brachytherapy and hormonal therapy. All patients were observed on an outpatient basis after the treatment. The analysis of TATI marker levels in correlation with the features of cancer were carried out after a 17-year-long follow-up period. TATI marker levels have been evaluated in patients with unfavorable predictors identified in the operation protocol and in the histopathological protocol of the removed tumor. It was found that TATI level in the fourth sampling after the treatment was the most important value. TATI level increase in this assay was significantly correlated with the occurrence of local relapse or distant metastasis. The comparison of the results of patients with and without surgical removal of the lymph nodes has shown a significantly longer disease-free period in patients whose lymph nodes were not removed.
PL
Marker TATI (tumor-associated trypsin inhibitor) najczęściej oceniany jest u chorych na raka jajnika. W pracy przedstawiono jego rolę i przydatność w ocenie wyników leczenia u chorych na raka trzonu macicy. Badanie prze­prowadzono na podstawie oceny poziomu markera TATI wśród 305 chorych na raka trzonu macicy leczonych w Centrum Onkologii w latach 1994–1995 w Warszawie. U każdej chorej wykonano od 3 do 7 oznaczeń markera z surowicy krwi po każdym z etapów leczenia uzupełniającego i w początkowym okresie obserwacji po zakończe­niu leczenia. W ocenie zaawansowania posługiwano się wówczas obowiązującym protokołem pooperacyjnym FIGO z 1988 roku i zgodnie z nim chore kwalifikowano do leczenia uzupełniającego, na które składały się telete­rapia, brachyterapia lub hormonoterapia. Wszystkie chore po leczeniu były obserwowane ambulatoryjnie. Analizę poziomów markera TATI w korelacji z cechami raka przeprowadzono po 17-letnim okresie obserwacji. Oceniono poziomy markera TATI w grupie chorych z niekorzystnymi czynnikami rokowniczymi stwierdzonymi na podstawie protokołu operacyjnego i histopatologicznego usuniętego guza nowotworowego. Stwierdzono, że poziom TATI w czwartym pobraniu, po ukończeniu leczenia jest najistotniejszą wartością. Wzrost poziomu TATI w tym ozna­czeniu znamiennie koreluje z wystąpieniem wznowy lub przerzutów odległych. Porównując wyniki leczenia opera­cyjnego bez usunięcia węzłów chłonnych i z ich usunięciem, stwierdzono znamiennie dłuższy czas wolny od cho­roby u chorych, u których nie były usuwane węzły chłonne.
Discipline
Year
Volume
11
Issue
2
Pages
103–114
Physical description
References
  • 1.Stenman U.H., Huhtala M.L., Koistinen R., Seppälä M.: Immunochemical demonstration of an ovarian cancer-associ­ated urinary peptide. Int. J. Cancer 1982; 30: 53–57.
  • 2.Duffy M.J.: Prognostic and predictive markers in cancer. J. Clin. Lig. Assay 1999; 22: 331–334.
  • 3.SPINK1 serine peptidase inhibitor, Kazal type 1 [Homo sapiens]. Gene ID: 6690. Adres: www.ncbi.nlm.nih.gov/gene/6690 [cyto­wany 10 lipca 2012 r.].
  • 4.Stenman U.H.: Tumor-associated trypsin inhibitor. Clin. Chem. 2002; 48: 1206–1209.
  • 5.Huhtala M.L., Pesonen K., Kalkkinen N., Stenman U.H.: Purification and characterization of a tumor-associated tryp­sin inhibitor from the urine of a patient with ovarian cancer. J. Biol. Chem. 1982; 257: 13713–13716.
  • 6.Stenman U.H., Koivunen E., Itkonen O., Halila H.: Clinical use and biological function of tumor-associated trypsin inhibitor (TATI). Edizioni Minerva Medica S.P.A., Torino 1993: 351–361.
  • 7.Marchbank T., Weaver G., Nilsen-Hamilton M., Playford R.J.: Pancreatic secretory trypsin inhibitor is a major motogenic and protective factor in human breast milk. Am. J. Physiol. Gastro­intest. Liver Physiol. 2009; 296: G697–G703.
  • 8.Marchbank T., Mahmood A., Fitzgerald A.J. i wsp.: Human pancreatic secretory trypsin inhibitor stabilizes intestinal muco­sa against noxious agents. Am. J. Pathol. 2007; 171: 1462–1473.
  • 9.Venesmaa P., Stenman U.H., Forss M. i wsp.: Pre-operative serum level of tumour-associated trypsin inhibitor and residu­al tumour size as prognostic indicators in stage III epithelial ovarian cancer. Br. J. Obstet. Gynaecol. 1998; 105: 508–511.
  • 10.Kobayashi K., Horiuchi M., Saheki T.: Pancreatic secretory trypsin inhibitor as a diagnostic marker for adult-onset type II citrullinemia. Hepatology 1997; 25: 1160–1165.
  • 11.Lasson A., Borgström A., Ohlsson K.: Elevated pancreatic secre­tory trypsin inhibitor levels during severe inflammatory disease, renal insufficiency, and after various surgical procedures. Scand. J. Gastroenterol. 1986; 21: 1275–1280.
  • 12.Miyata S., Koshikawa N., Higashi S. i wsp.: Expression of trypsin in human cancer cell lines and cancer tissues and its tight binding to soluble form of Alzheimer amyloid precursor protein in culture. J. Biochem. 1999; 125: 1067–1076.
  • 13. Halila H., Lehtovirta P., Stenman U.H., Seppälä M.: CA 125 in the follow-up of patients with ovarian cancer. Acta Obstet. Gynecol. Scand. 1988; 67: 53–58.
  • 14. Peters-Engl C., Medl M., Ogris E., Leodolter S.: Tumor-asso­ciated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in patients with epithelial ovarian cancer. Anticancer Res. 1995; 15: 2727–2730.
  • 15. Patton P.E., Field C.S., Harms R.W., Coulam C.B.: CA-125 levels in endometriosis. Fertil. Steril. 1986; 45: 770–773.
  • 16. Barbieri R.L., Niloff J.M., Bast R.C. Jr i wsp.: Elevated serum concentrations of CA-125 in patients with advanced endome­triosis. Fertil. Steril. 1986; 45: 630–634.
  • 17. Järvisalo J., Hakama M., Knekt P. i wsp.: Serum tumor markers CEA, CA 50, TATI, and NSE in lung cancer screening. Cancer 1993; 71: 1982–1988.
  • 18. Sjöström J., Alfthan H., Joensuu H. i wsp.: Serum tumour markers CA 15-3, TPA, TPS, hCGβ and TATI in the monitor­ing of chemotherapy response in metastatic breast cancer. Scand. J. Clin. Lab. Invest. 2001; 61: 431–441.
  • 19. Paju A., Hotakainen K., Cao Y. i wsp.: Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells. Eur. Urol. 2007; 52: 1670–1679.
  • 20. Pectasides D., Bafaloucos D., Antoniou F. i wsp.: TPA, TATI, CEA, AFP, β-HCG, PSA, SCC, and CA 19-9 for monitoring transitional cell carcinoma of the bladder. Am. J. Clin. Oncol. 1996; 19: 271–277.
  • 21. Taccone W., Mazzon W., Belli M.: Evaluation of TATI and other markers in solid tumors. Scand. J. Clin. Lab. Invest. Suppl. 1991; 207: 25–32.
  • 22. Satake K., Inui A., Sogabe T. i wsp.: The measurement of serum immunoreactive pancreatic secretory trypsin inhibitor in gastrointestinal cancer and pancreatic disease. Int. J. Pan­creatol. 1988; 3: 323–331.
  • 23. Pasanen P., Eskelinen M., Kulju A. i wsp.: Tumour-associated trypsin inhibitor (TATI) in patients with colorectal cancer: a comparison with CEA, CA 50 and CA 242. Scand. J. Clin. Lab. Invest. 1995; 55: 119–124.
  • 24. Solakidi S., Dessypris A., Stathopoulos G.P. i wsp.: Tumour-as­sociated trypsin inhibitor, carcinoembryonic antigen and acute-phase reactant proteins CRP and α1-antitrypsin in patients with gastrointestinal malignancies. Clin. Biochem. 2004; 37: 56–60.
  • 25. Aalders J.G., Thomas G.: Endometrial cancer – revisiting the importance of pelvic and para aortic lymph nodes. Gynecol. Oncol. 2007; 104: 222–231.
  • 26. Frumovitz M., Bodurka D.C., Broaddus R.R. i wsp.: Lym­phatic mapping and sentinel node biopsy in women with high-risk endometrial cancer. Gynecol. Oncol. 2007; 104: 100–103.
  • 27. Benedetti Panici P., Basile S., Maneschi F. i wsp.: Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J. Natl Cancer Inst. 2008; 100: 1707–1716.
  • 28. Trovik J., Wik E., Stefansson I.M. i wsp.: Stathmin overexpres­sion identifies high-risk patients and lymph node metastasis in endometrial cancer. Clin. Cancer Res. 2011; 17: 3368–3377.
Document Type
article
Publication order reference
YADDA identifier
bwmeta1.element.psjd-ef20881f-721c-40f3-8102-ee50d329f964
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.